title: Effect of viscous macromolecules on peritoneal plasminogen activator activity: a potential mechanism for their ability to reduce postoperative adhesion formation.
abstract: Activity of peritoneal plasminogen activator and its regulation by dextran and other macromolecules that clinically suppress postoperative adhesions was studied. Plasminogen activator activity was assayed by a two-stage globinolytic assay that monitors formation of plasmin, as well as by cleavage of a chromogenic peptide substrate (S-2444) in the presence of aprotinin (Trasylol). Plasminogen activator activity was located on the outer surface of human peritoneum. Incubation of peritoneal tissue with buffer in vitro (conditioning) prompted release of plasminogen activator into the conditioning medium. The released plasminogen activator formed a single band on sodium dodecyl sulfate-gel electrophoresis at an apparent molecular weight of 174,000 and was markedly suppressed by antiserum raised against human melanoma tissue-type plasminogen activator. Nonspecific proteolytic activity did not accumulate in the medium during conditioning. The presence of dextran 80 during conditioning of peritoneum reversibly suppressed tissue-bound plasminogen activator activity and reduced plasminogen activator activity in the spent medium. A similar inhibition of peritoneal plasminogen activator was induced by dextran 500, methyl cellulose, and polyvinylpyrrolidone. Dextran, when added to the medium after conditioning, had no direct inhibitory effect on plasminogen activator activity. Dextran did not induce peritoneal production of inhibitor(s) of trypsin, chymotrypsin, or urokinase. On the basis of these findings, two possible mechanisms for the effect of viscous polymers in the reduction of adhesion formation are proposed. These mechanisms consider the importance of peritoneal tissue-type plasminogen activator for removal of fibrin clots and suggest that polymer coating either prevents the shedding of plasminogen activator into the abdominal cavity or reduces the access of fibrin clots to the serosal surfaces.
authors: Department of Clinical Biochemistry, Hebrew University-Hadassah Medical School, Mount Scopus Hospital, Jerusalem, Israel.
authors: M
authors: M
authors: Mayer
authors: S
authors: S
authors: Yedgar
authors: A
authors: A
authors: Hurwitz
authors: Z
authors: Z
authors: Palti
authors: Z
authors: Z
authors: Finzi
authors: A
authors: A
authors: Milwidsky
mesh_terms: D000005:Abdomen / Q000473:pathology; D003911:Dextrans / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D046911:Macromolecular Substances; D008747:Methylcellulose / Q000494:pharmacology; D010537:Peritoneum / Q000378:metabolism*; D010960:Plasminogen Activators / Q000378:metabolism*; D011183:Postoperative Complications / Q000517:prevention & control; D011205:Povidone / Q000494:pharmacology; D000267:Tissue Adhesions / Q000378:metabolism / Q000517:prevention & control*; D014783:Viscosity
chemical_list: D003911:Dextrans; D046911:Macromolecular Substances; D008747:Methylcellulose; D010960:Plasminogen Activators; D011205:Povidone